*September 2020* Note: this is in context of HER2, another resistance mechanism of EGFR TKIs. Trastuzumab deruxtecan has demonstrated impressive
*September 2020* The first targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) harboring MET mutations, capmatinib (Tabrecta),
*September 2020* A small-molecule inhibitor targeting a KRAS mutation achieved a high rate of disease control in a preliminary study of patients
*September 2020* Additionally, the findings showed that BLU-945 potently and selectively inhibited triple-mutant EGFR, harboring the most common on-target resistance
*September 2020* The combination of osimertinib and bevacizumab did not prolong progression-free survival in patients with advanced adenocarcinoma who had
*September 2020* The combination of amivantamab (JNJ-61186372; JNJ-6372) and lazertinib demonstrated high response rates and was well tolerated in treatment-naïve
*September 2020* Dual inhibition of both VEGFR and EGFR with the combination of apatinib and gefitinib in the first-line treatment
*October 2020* by Tess Taft, msw, licsw ©all rights reserved This is the fifth part of a seven-part series on
*September 2020* Nathan A. Pennell, MD, PhD, an associate professor in the Department of Medicine and director of the Lung Cancer Medical
*August 2020* The FDA has granted a priority review designation to new drug application (NDA) for tepotinib as a treatment
